bioshares report, page-32

re BARDA, from company announcement of 18 Feb 2013:

"Funds from a successful BARDA contract would allow NovoSkin to accelerate the development of the BTM treatment for third degree burn wounds and undergo the Pre-Marketing Approval (PMA) clinical trials required to allow marketing of BTM for this application in the United States."

The money from BARDA would accelerate development. It's a strange perspective to then turn around and say that development will be "delayed" if the BARDA contract does not come through, as HANDDONTCOUNT purports.

The BARDA grant/contract would be hugely positive, no question; it would be seen as validating the underlying technology, it would speed up development, and it would get the attention of potential partners as well as the general market.

But, it needs to be kept in perspective, as you have done.